Hinge Health Inc. (NYSE:HNGE) Stock Has Average Price Target of $108.00 According to Brokerages

Shares of Hinge Health Inc. (NYSE:HNGE) have been assigned a consensus recommendation of “Moderate Buy” from the nineteen analysts that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $108.00.

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Hinge Health from $90.00 to $103.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Needham & Company LLC increased their price target on shares of Hinge Health from $97.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, September 30th. Royal Bank Of Canada lifted their price target on Hinge Health from $75.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group set a $105.00 price objective on Hinge Health in a report on Wednesday, August 5th. Finally, Barclays upped their price objective on Hinge Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Monday, October 12th.

Hinge Health News Summary

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Quarterly results exceeded published estimates. Hinge Health reported adjusted earnings of approximately $0.71 per share, above consensus estimates ranging from $0.27 to $0.63, while revenue reached $234.97 million versus a FactSet estimate of $224.8 million. Hinge Health beats Q3 earnings and revenue estimates
• Positive Sentiment: Growth and profitability remained strong. Revenue increased 52.4% year over year, compared with a loss in the prior-year quarter. The company posted a 15.15% net margin and 51.6% return on equity, reinforcing the investment case for its digital musculoskeletal-care platform. Hinge Health reports record third quarter 2026 financial results
• Positive Sentiment: The company reportedly delivered a third consecutive outlook increase. That signals continued operating momentum and may support investor confidence in Hinge Health’s ability to scale care delivery and automate its technology platform. Hinge Health clears consensus but misses the whisper
• Neutral Sentiment: CEO Daniel Perez also discussed the business with Jim Cramer, providing additional visibility for the company’s growth strategy and clinical-cost savings proposition. Hinge Health CEO interview
• Negative Sentiment: Expectations and valuation remain risks. Some coverage indicated the results fell short of elevated “whisper” expectations, while HNGE trades near its 12-month high at a high earnings multiple. Consequently, strong reported results may already be substantially reflected in the share price.

Hinge Health Trading Up 0.7%

Hinge Health stock opened at $115.11 on Thursday. Hinge Health has a 52 week low of $30.08 and a 52 week high of $118.87. The stock has a market cap of $9.29 billion, a P/E ratio of 89.36 and a beta of 1.37. The stock has a 50 day moving average of $98.66 and a 200-day moving average of $67.35.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.44. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The firm had revenue of $234.97 million for the quarter. During the same period in the prior year, the company earned ($0.02) earnings per share. The company’s revenue was up 52.4% on a year-over-year basis. As a group, equities analysts predict that Hinge Health will post 1.25 earnings per share for the current fiscal year.

Insider Transactions at Hinge Health

In related news, Chairman Gabriel Mecklenburg sold 200,000 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $103.13, for a total transaction of $20,626,000.00. Following the sale, the chairman directly owned 200,000 shares of the company’s stock, valued at approximately $20,626,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Budge sold 47,720 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $103.13, for a total value of $4,921,363.60. Following the transaction, the chief financial officer owned 296,728 shares in the company, valued at $30,601,558.64. This trade represents a 13.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,024,581 shares of company stock valued at $95,632,761 over the last 90 days. Insiders own 18.92% of the company’s stock.

Institutional Investors Weigh In On Hinge Health

A number of institutional investors have recently modified their holdings of the business. 11.2 Capital Management LLC acquired a new stake in shares of Hinge Health during the 2nd quarter worth approximately $204,566,531. Assenagon Asset Management S.A. boosted its position in Hinge Health by 2,141.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company’s stock valued at $180,373,000 after purchasing an additional 1,772,182 shares during the period. Wellington Management Group LLP grew its stake in Hinge Health by 169.7% during the 2nd quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock worth $100,063,000 after buying an additional 758,594 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Hinge Health by 225.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock worth $44,852,000 after buying an additional 806,007 shares during the last quarter. Finally, Estuary Capital Management LP acquired a new stake in Hinge Health in the first quarter worth $15,201,000.

Hinge Health Company Profile

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.